GlassScriptPhysician profile
Laura Sharmini Lourdes
NPI 1871806349
$10,543.76
in general payments reported to CMS, 2019-2025
49 companies · $585 in 2025
The $585 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.10 · 2020: $41.72 · 2021: $2,654 · 2022: $279 · 2023: $1,561 · 2024: $5,410 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $4,550 · Food and Beverage: $2,101 · Travel and Lodging: $905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $4,550.00 |
| Food and Beverage | $2,100.70 |
| Travel and Lodging | $904.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $5,908.02 | 2023-2024 | Optune Lua (Novottf-200t), Optune |
| Eli Lilly and Company | $2,250.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $274.87 | 2021-2025 | |
| Gilead Sciences, INC. | $203.96 | 2021-2024 | Trodelvy |
| Genzyme Corporation | $181.99 | 2021-2022 | |
| Pfizer INC. | $148.58 | 2020-2025 | |
| Medtronic, INC. | $134.93 | 2023 | Synchromedii |
| Janssen Biotech, INC. | $121.81 | 2024-2025 | Talvey, Darzalex, Rybrevant |
| Glaxosmithkline, LLC. | $106.39 | 2024 | Benlysta |
| Mirati Therapeutics, INC. | $103.22 | 2023 | Krazati |
| Macrogenics, INC. | $93.11 | 2022 | |
| Foundation Medicine, INC. | $89.23 | 2021 | |
| Janssen Scientific Affairs, LLC | $83.21 | 2025 | Darzalex, Carvykti, Tecvayli |
| Genentech USA, INC. | $78.11 | 2021-2023 | Polivy |
| Tempus Ai, INC | $64.55 | 2024-2025 | Xt Cdx |
Show all 44 companies
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Lourdes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.